Clinical Catch-Up: January 18-22 | BioSpace
The Pharma Data
JANUARY 24, 2021
CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. Quantum Genomics launched its Phase III REFRESH trial in difficult-to-treat or resistant hypertension. It is being administered together with FOLFOX chemotherapy.
52 
Let's personalize your content